5-BrdU
Based on 82 publication(s) in Google Scholar
5-BrdU (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 59-14-3
- Formule: C9H11BrN2O5
- Masse moléculaire:307.10
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 5-BrdU
More- Nature. 2026 Apr;652(8109):442-450. [Abstract]
- J Hematol Oncol. 2025 Apr 1;18(1):38. [Abstract]
- J Clin Oncol. 2025 Mar;43(7):840-851. [Abstract]
- Cell Metab. 2026 May 5;38(5):963-980.e12. [Abstract]
- Cell Res. 2020 Sep;30(9):732-744. [Abstract]
- Cell Res. 2019 Jan;29(1):23-41. [Abstract]
- Immunity. 2024 Mar 12;57(3):495-512.e11. [Abstract]
- Immunity. 2023 Mar 14;56(3):620-634.e11. [Abstract]
- Adv Mater. 2025 Oct 21:e10824. [Abstract]
- Nat Cancer. 2022 Sep;3(9):1052-1070. [Abstract]
- Nat Metab. 2021 May;3(5):682-700. [Abstract]
- Autophagy. 2022 Nov;18(11):2711-2730. [Abstract]
- Nat Commun. 2022 Jan 10;13(1):182. [Abstract]
- Adv Sci (Weinh). 2025 Jun 29:e09533. [Abstract]
- Sci Adv. 2025 Jul 11;11(28):eadw1553. [Abstract]
- Cell Death Differ. 2025 Jul 19. [Abstract]
- Cell Death Dis. 2022 Sep 20;13(9):803. [Abstract]
- Cell Death Dis. 2020 Apr 6;11(4):219. [Abstract]
- J Immunother Cancer. 2023 Aug;11(8):e007286. [Abstract]
- NPJ Biofilms Microbiomes. 2025 May 23;11(1):86. [Abstract]
- Phytomedicine. 2024 Jun:128:155464. [Abstract]
- Burns Trauma. 2025 Oct 24.
- Phytother Res. 2025 Jul;39(7):3241-3253. [Abstract]
- Phytother Res. 2025 Apr 27. [Abstract]
- Free Radic Biol Med. 2024 May 9:221:1-12. [Abstract]
- Clin Transl Med. 2025 Feb;15(2):e70243. [Abstract]
- Cell Rep. 2026 Apr 25;45(5):117297. [Abstract]
- Cell Rep. 2024 Aug 5;43(8):114584. [Abstract]
- Cell Rep. 2024 Mar 18;43(3):113930. [Abstract]
- Cell Rep. 2021 Apr 13;35(2):108952. [Abstract]
- Br J Pharmacol. 2026 Jul;183(13):3558-3577. [Abstract]
- Transl Psychiatry. 2023 Aug 14;13(1):280. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Mol Cancer Ther. 2025 Dec 31. [Abstract]
- J Ethnopharmacol. 2025 Apr 9:345:119619. [Abstract]
- Hepatol Commun. 2022 Sep;6(9):2340-2353. [Abstract]
- Commun Biol. 2023 Jan 16;6(1):55. [Abstract]
- Pharmaceuticals (Basel). 2026 Apr 8;19(4):601. [Abstract]
- Pharmaceuticals (Basel). 2021 Jan 6;14(1):38. [Abstract]
- Stem Cell Reports. 2026 Jun 9;21(6):102927. [Abstract]
- Stem Cell Reports. 2021 Jun 8;16(6):1568-1583. [Abstract]
- Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):648-655. [Abstract]
- Mol Neurobiol. 2025 Apr;62(4):5252-5272. [Abstract]
- Mol Neurobiol. 2024 Oct;61(10):8293-8306. [Abstract]
- Glia. 2022 Feb;70(2):379-392. [Abstract]
- Arthritis Res Ther. 2023 Nov 9;25(1):217. [Abstract]
- Chem Biol Interact. 2026 Aug 1:436:112210. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Oct 15;1871(1):167542. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- J Mol Cell Cardiol. 2018 May:118:133-146. [Abstract]
- Obesity (Silver Spring). 2017 Sep;25(9):1532-1539. [Abstract]
- iScience. 2025 Nov 5;28(12):113949. [Abstract]
- FASEB J. 2024 Nov 15;38(21):e70138. [Abstract]
- J Cell Physiol. 2020 Jul;235(7-8):5764-5776. [Abstract]
- J Cell Physiol. 2020 Mar;235(3):2963-2972. [Abstract]
- Exp Cell Res. 2020 Dec 1;397(1):112311. [Abstract]
- Genes (Basel). 2024 Sep 13;15(9):1206. [Abstract]
- Immunopharmacol Immunotoxicol. 2022 Oct;44(5):746-756. [Abstract]
- Virology. 2024 Dec:600:110237. [Abstract]
- Biochem Biophys Res Commun. 2021 May 21:554:214-221. [Abstract]
- Cardiovasc Eng Technol. 2019 Dec;10(4):638-647. [Abstract]
- Exp Ther Med. 2018 Jun;15(6):5269-5274. [Abstract]
- Asia Pac J Clin Oncol. 2025 Feb;21(1):12-30. [Abstract]
- J Interferon Cytokine Res. 2023 May;43(5):216-228. [Abstract]
- Am J Transl Res. 2016 Sep 15;8(9):3955-3962. [Abstract]
- Am J Transl Res. 2016 Jun 15;8(6):2562-74. [Abstract]
- J Surg Res. 2022 Dec:280:429-439. [Abstract]
- Viral Immunol. 2025 Jun;38(5):180-189. [Abstract]
- Neuropathology. 2023 Oct;43(5):362-372. [Abstract]
- University of Pennsylvania. 2025.
- Biomed Pharmacother. 2025 Aug:189:118267. [Abstract]
- bioRxiv. 2024 August 22.
- SSRN. 2024 Apr 19.
- Research Square Preprint. 2024 Jan 5.
- Biomed Pharmacother. 2023 Dec 31:169:115880. [Abstract]
- Research Square Preprint. 2023 Dec 16.
- Biomed Pharmacother. 2023 Nov:167:115618. [Abstract]
- bioRxiv. 2023 Jun 22.
- Research Square Print. 2022 Aug.
- bioRxiv. January 25, 2022.
- Research Square Preprint. 2021 Oct.
- bioRxiv. August 31, 2021.
Customer Validation & Images
-
IF
-
IF
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L5178Y | IC50 |
12 μM
Compound: BrdUrd
|
In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells
In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells
|
[PMID: 11101356] |
| L5178Y | IC50 |
20 μM
Compound: BrdUrd
|
In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.
In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.
|
[PMID: 11101356] |
| L5178Y | IC50 |
26 μM
Compound: BrdUrd
|
In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.
In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.
|
[PMID: 11101356] |
| L5178Y | IC50 |
26 μM
Compound: BrdUrd
|
In vitro growth inhibition of L5178Y-Parental murine leukemia cells
In vitro growth inhibition of L5178Y-Parental murine leukemia cells
|
[PMID: 11101356] |
Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion RG2 rat glioma cells. In H9 cells and BJ fibroblasts, bromodeoxyuridine alters the cell cycle profile[1]. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 59-14-3
-
Appearance Solid
-
Masse moléculaire 307.10
-
Formule C9H11BrN2O5
-
Color White to off-white
-
SMILES
O[C@H]1C[C@H](N2C(NC(C(Br)=C2)=O)=O)O[C@@H]1CO
-
Synonyms
BrdU; 5-Bromo-2'-deoxyuridine; BUdR
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (82)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Apr;652(8109):442-450. PMID: 41813891 -
J Hematol Oncol
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function. [Abstract]2025 Apr 1;18(1):38. PMID: 40170099 -
J Clin Oncol
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. [Abstract]2025 Mar;43(7):840-851. PMID: 39475591 -
Cell Metab
Psoriasis modulates inflammatory bowel disease risk and intestinal epithelium lipid metabolism via IL-1β-producing macrophages. [Abstract]2026 May 5;38(5):963-980.e12. PMID: 41856104 -
Cell Res
2020 Sep;30(9):732-744. PMID: 32355287 -
Cell Res
2019 Jan;29(1):23-41. PMID: 30514900 -
Immunity
Disruption of the Na+/K+-ATPase-purinergic P2X7 receptor complex in microglia promotes stress-induced anxiety. [Abstract]2024 Mar 12;57(3):495-512.e11. PMID: 38395698 -
Immunity
Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. [Abstract]2023 Mar 14;56(3):620-634.e11. PMID: 36854305 -
Adv Mater
Injectable Conductive Hydrogel Patch with Spatiotemporally Tailored Asymmetric Adhesion for Myocardial Infarction Repair. [Abstract]2025 Oct 21:e10824. PMID: 41117075 -
Nat Cancer
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. [Abstract]2022 Sep;3(9):1052-1070. PMID: 35773527 -
Nat Metab
In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR. [Abstract]2021 May;3(5):682-700. PMID: 34031592 -
Autophagy
RTN4/Nogo-A-S1PR2 negatively regulates angiogenesis and secondary neural repair through enhancing vascular autophagy in the thalamus after cerebral cortical infarction. [Abstract]2022 Nov;18(11):2711-2730. PMID: 35263212 -
Nat Commun
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. [Abstract]2022 Jan 10;13(1):182. PMID: 35013322 -
Adv Sci (Weinh)
Tryptophan Metabolite Indole-3-Aldehyde Induces AhR and c-MYC Degradation to Promote Tumor Immunogenicity. [Abstract]2025 Jun 29:e09533. PMID: 40583248 -
Sci Adv
Transition of cellular senescence to pyroptosis mediates recurrence of small cell lung cancer after chemotherapy. [Abstract]2025 Jul 11;11(28):eadw1553. PMID: 40644541 -
Cell Death Differ
FMRP regulation of STAT3-MYC signaling is critical for adult hippocampal neurogenesis and cognitive flexibility. [Abstract]2025 Jul 19. PMID: 40683950 -
Cell Death Dis
Hnrnpk maintains chondrocytes survival and function during growth plate development via regulating Hif1α-glycolysis axis. [Abstract]2022 Sep 20;13(9):803. PMID: 36127325 -
Cell Death Dis
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. [Abstract]2020 Apr 6;11(4):219. PMID: 32249776 -
J Immunother Cancer
2023 Aug;11(8):e007286. PMID: 37586772 -
NPJ Biofilms Microbiomes
Akkermansia muciniphila ameliorates doxorubicin-induced cardiotoxicity by regulating PPARα-dependent mitochondrial biogenesis. [Abstract]2025 May 23;11(1):86. PMID: 40410194 -
Phytomedicine
Lycorine inhibits Ang II-induced heart remodeling and inflammation by suppressing the PI3K-AKT/NF-κB pathway. [Abstract]2024 Jun:128:155464. PMID: 38484625 -
-
Phytother Res
Biochanin a Alleviated Doxorubicin-Induced Cardiotoxicity but Did not Interfere With the Antitumor Effect of Doxorubicin. [Abstract]2025 Jul;39(7):3241-3253. PMID: 40514798 -
Phytother Res
Portulaca oleracea L. Extract and Its Alkaloid Oleracein E Alleviates Cardiac Remodeling and Heart Failure in Mice by Targeting STAT2 Through the MAPK Signaling Inflammatory Pathway. [Abstract]2025 Apr 27. PMID: 40289247 -
Free Radic Biol Med
Isoliquiritigenin alleviates myocardial ischemia-reperfusion injury by regulating the Nrf2/HO-1/SLC7a11/GPX4 axis in mice. [Abstract]2024 May 9:221:1-12. PMID: 38734270 -
Clin Transl Med
Ubiquitin-specific protease 25 improves myocardial ischemia-reperfusion injury by deubiquitinating NLRP3 and negatively regulating NLRP3 inflammasome activity in cardiomyocytes. [Abstract]2025 Feb;15(2):e70243. PMID: 39985261 -
Cell Rep
SEPHS2 loss reprograms cancer metabolism from oxidative phosphorylation to gluconeogenesis via PCK1 stabilization. [Abstract]2026 Apr 25;45(5):117297. PMID: 42035418 -
Cell Rep
Oxidative stress reprograms the transcriptional coactivator Yki to suppress cell proliferation. [Abstract]2024 Aug 5;43(8):114584. PMID: 39106181 -
Cell Rep
PRRC2B modulates oligodendrocyte progenitor cell development and myelination by stabilizing Sox2 mRNA. [Abstract]2024 Mar 18;43(3):113930. PMID: 38507412 -
Cell Rep
Mitochondrial biogenesis in developing astrocytes regulates astrocyte maturation and synapse formation. [Abstract]2021 Apr 13;35(2):108952. PMID: 33852851 -
Br J Pharmacol
The deubiquitinase YOD1 in cardiomyocytes mediates septic cardiomyopathy by deubiquitinating and thus stabilizing the NLRP3 inflammasome. [Abstract]2026 Jul;183(13):3558-3577. PMID: 41913386 -
Transl Psychiatry
HSPA12A controls cerebral lactate homeostasis to maintain hippocampal neurogenesis and mood stabilization. [Abstract]2023 Aug 14;13(1):280. PMID: 37580315 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Mol Cancer Ther
PM534, a Novel Colchicine‑Site Tubulin Inhibitor with Broad‑Spectrum and Resistance‑Overcoming Antitumor Activity. [Abstract]2025 Dec 31. PMID: 41481906 -
J Ethnopharmacol
Lancao decoction alleviates Alzheimer's disease: Depending on activating CaMKII to protect neuronal refunction by reducing β-amyloid in the hippocampus. [Abstract]2025 Apr 9:345:119619. PMID: 40074096 -
Hepatol Commun
Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy. [Abstract]2022 Sep;6(9):2340-2353. PMID: 35509206 -
Commun Biol
Hippocampal dentate gyri proteomics reveals Wnt signaling involvement in the behavioral impairment in the THRSP-overexpressing ADHD mouse model. [Abstract]2023 Jan 16;6(1):55. PMID: 36646879 -
Pharmaceuticals (Basel)
Shengmai San Ameliorates High-Glucose-Induced Calcium Homeostasis Imbalance via Improving Energy Metabolism in Neonatal Rat Cardiomyocytes. [Abstract]2026 Apr 8;19(4):601. PMID: 42075856 -
Pharmaceuticals (Basel)
Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer. [Abstract]2021 Jan 6;14(1):38. PMID: 33419162 -
Stem Cell Reports
miR-151-5p regulates neural stem cell fate by targeting APH1A to modulate Notch signaling gradients. [Abstract]2026 Jun 9;21(6):102927. PMID: 42167224 -
Stem Cell Reports
Photobiomodulation therapy for hair regeneration: A synergetic activation of β-CATENIN in hair follicle stem cells by ROS and paracrine WNTs. [Abstract]2021 Jun 8;16(6):1568-1583. PMID: 34019818 -
Artif Cells Nanomed Biotechnol
Silencing circular RNA-ZNF652 represses proliferation and EMT process of renal carcinoma cells via raising miR-205. [Abstract]2020 Dec;48(1):648-655. PMID: 32070139 -
Mol Neurobiol
Alpha‑Asarone Ameliorates Neuronal Injury After Ischemic Stroke and Hemorrhagic Transformation by Attenuating Blood-Brain Barrier Destruction, Promoting Neurogenesis, and Inhibiting Neuroinflammation. [Abstract]2025 Apr;62(4):5252-5272. PMID: 39531192 -
Mol Neurobiol
Influenza A Virus PB1-F2 Induces Affective Disorder by Interfering Synaptic Plasticity in Hippocampal Dentate Gyrus. [Abstract]2024 Oct;61(10):8293-8306. PMID: 38488981 -
Glia
2022 Feb;70(2):379-392. PMID: 34724258 -
Arthritis Res Ther
Rspo2 exacerbates rheumatoid arthritis by targeting aggressive phenotype of fibroblast-like synoviocytes and disrupting chondrocyte homeostasis via Wnt/β-catenin pathway. [Abstract]2023 Nov 9;25(1):217. PMID: 37946278 -
Chem Biol Interact
F-53B exacerbates doxorubicin-induced cardiotoxicity by impairing NRF2-dependent ferroptosis defense. [Abstract]2026 Aug 1:436:112210. PMID: 42297177 -
Biochim Biophys Acta Mol Basis Dis
PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis. [Abstract]2024 Oct 15;1871(1):167542. PMID: 39419453 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
J Mol Cell Cardiol
MicroRNA-223 protects neonatal rat cardiomyocytes and H9c2 cells from hypoxia-induced apoptosis and excessive autophagy via the Akt/mTOR pathway by targeting PARP-1. [Abstract]2018 May:118:133-146. PMID: 29608885 -
Obesity (Silver Spring)
2017 Sep;25(9):1532-1539. PMID: 28726347
5-BrdU purchased from MedChemExpress. Usage Cited in: Obesity (Silver Spring). 2017 Sep;25(9):1532-1539. [Abstract]
Representative images for BrdU staining, followed by semiquantitative analysis.
-
iScience
Microglial Prrc2a regulates microglia-neuron interaction in cerebellum and motor functions in mice. [Abstract]2025 Nov 5;28(12):113949. PMID: 41341849 -
FASEB J
Abnormal hippocampal neurogenesis and impaired social recognition memory in two neurodevelopmental models of schizophrenia. [Abstract]2024 Nov 15;38(21):e70138. PMID: 39485229 -
J Cell Physiol
IFN-γ/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation. [Abstract]2020 Jul;235(7-8):5764-5776. PMID: 31970777 -
J Cell Physiol
Propofol exerts anticancer activity on hepatocellular carcinoma cells by raising lncRNA DGCR5. [Abstract]2020 Mar;235(3):2963-2972. PMID: 31538334 -
Exp Cell Res
NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling. [Abstract]2020 Dec 1;397(1):112311. PMID: 32991874 -
Genes (Basel)
CHIR99021 and Brdu Are Critical in Chicken iPSC Reprogramming via Small-Molecule Screening. [Abstract]2024 Sep 13;15(9):1206. PMID: 39336797 -
Immunopharmacol Immunotoxicol
LINC00174 promotes cell proliferation and metastasis in renal clear cell carcinoma by regulating miR-612/FOXM1 axis. [Abstract]2022 Oct;44(5):746-756. PMID: 35616230 -
Virology
5-Bromo-2'-deoxyuridine inhibits African swine fever virus (ASFV) replication via interfering viral DNA replication and suppressing the formation of viral factories. [Abstract]2024 Dec:600:110237. PMID: 39288610 -
Biochem Biophys Res Commun
2021 May 21:554:214-221. PMID: 33813077 -
Cardiovasc Eng Technol
Cilostazol Promotes Angiogenesis and Increases Cell Proliferation After Myocardial Ischemia-Reperfusion Injury Through a cAMP-Dependent Mechanism. [Abstract]2019 Dec;10(4):638-647. PMID: 31625080 -
Exp Ther Med
Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway. [Abstract]2018 Jun;15(6):5269-5274. PMID: 29805545
5-BrdU purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2018 Jun;15(6):5269-5274. [Abstract]
Detection of the effects of CGS 20267 and the MAPK pathway on the proliferation of GC-1 spg cells by BrdU. MAPK, mitogen-activated protein kinase; spg, spermatogonia; BrdU, bromodeoxyuridine.
-
Asia Pac J Clin Oncol
The prognostic and immune significance of Rab11A in pan-cancer and its function and mechanism underlying estrogen receptor targeting in breast cancer. [Abstract]2025 Feb;21(1):12-30. PMID: 39395024 -
J Interferon Cytokine Res
Remote Ischemic Conditioning Relieves Necrotizing Enterocolitis Through Regulation of Redox and Inflammation. [Abstract]2023 May;43(5):216-228. PMID: 37103522 -
Am J Transl Res
2016 Sep 15;8(9):3955-3962. PMID: 27725875 -
Am J Transl Res
Growing a whole porcine liver organ ex situ for six hours without red blood cells or hemoglobin. [Abstract]2016 Jun 15;8(6):2562-74. PMID: 27398140
5-BrdU purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2016 Jun 15;8(6):2562-74. [Abstract]
BrdU hepatocyte proliferative assay in ESLC. The representative tissue containing BrdU-positive cells taken after 6 hours of ESLC is shown in (A), and two newly proliferated neighboring positive cells is enlarged and inserted on the right side. (B) shows the experimental negative control and (C) is the analyzed number of BrdU-positive hepatocytes in comparison with control.
-
J Surg Res
Hypoxia-Inducible Factor 1α Stability Modified by Glutaredoxin-1 in Necrotizing Enterocolitis. [Abstract]2022 Dec:280:429-439. PMID: 36049244 -
Viral Immunol
Vesicular Stomatitis Virus Induces NF-κB-Dependent Senescence to Mediate Persistent Inflammation and Injury. [Abstract]2025 Jun;38(5):180-189. PMID: 40401441 -
Neuropathology
Intracerebral hirudin injection alleviates cognitive impairment and oxidative stress and promotes hippocampal neurogenesis in rats subjected to cerebral ischemia. [Abstract]2023 Oct;43(5):362-372. PMID: 36918198 -
-
Biomed Pharmacother
Ugonin L ameliorates pulmonary fibrosis as a novel TβRs inhibitor by regulating the TGF-β/TβRs signaling and autophagy. [Abstract]2025 Aug:189:118267. PMID: 40532575 -
-
-
-
Biomed Pharmacother
20(S)-ginsenoside Rh2 inhibits angiotensin-2 mediated cardiac remodeling and inflammation associated with suppression of the JNK/AP-1 pathway. [Abstract]2023 Dec 31:169:115880. PMID: 37956481 -
-
Biomed Pharmacother
Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3. [Abstract]2023 Nov:167:115618. PMID: 37793277 -
-
-
-
-
Solvant et solubilité
DMSO : 250 mg/mL (814.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 2 mg/mL (6.51 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 14.29 mg/mL (46.53 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 µM BrdU for 24 hours, and cumulative growth curves are obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16. [Content Brief]
[2]. Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.2563 mL | 16.2813 mL | 32.5627 mL | 81.4067 mL |
| 5 mM | 0.6513 mL | 3.2563 mL | 6.5125 mL | 16.2813 mL | |
| DMSO | 10 mM | 0.3256 mL | 1.6281 mL | 3.2563 mL | 8.1407 mL |
| 15 mM | 0.2171 mL | 1.0854 mL | 2.1708 mL | 5.4271 mL | |
| 20 mM | 0.1628 mL | 0.8141 mL | 1.6281 mL | 4.0703 mL | |
| 25 mM | 0.1303 mL | 0.6513 mL | 1.3025 mL | 3.2563 mL | |
| 30 mM | 0.1085 mL | 0.5427 mL | 1.0854 mL | 2.7136 mL | |
| 40 mM | 0.0814 mL | 0.4070 mL | 0.8141 mL | 2.0352 mL | |
| 50 mM | 0.0651 mL | 0.3256 mL | 0.6513 mL | 1.6281 mL | |
| 60 mM | 0.0543 mL | 0.2714 mL | 0.5427 mL | 1.3568 mL | |
| 80 mM | 0.0407 mL | 0.2035 mL | 0.4070 mL | 1.0176 mL | |
| 100 mM | 0.0326 mL | 0.1628 mL | 0.3256 mL | 0.8141 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
5-BrdU Related Classifications
HY-15910 Related Classifications
Powered by Bioz